HAPV3 after 2Q26: ticket growth holds revenue while cash MLR, litigation, and portfolio cleanup squeeze adjusted EBITDA
How to read Hapvida’s second-quarter package — R$7.97bn net revenue (+3.9%), cash medical loss ratio at 75.2%, adjusted EBITDA R$504m (6.3% margin), adjusted net income R$12.5m, ~947k lives under contract review, judicial claims up R$37m sequentially, and net debt at R$5.40bn (1.61x LTM EBITDA).
HAPV3 after 2Q26: ticket growth holds revenue while cash MLR, litigation, and portfolio cleanup squeeze adjusted EBITDA
On 13 August 2026, Hapvida Participações e Investimentos S.A. (B3: HAPV3) published its 2Q26 results for the period ended 30 June 2026. Net revenue reached R$ 7.97 billion (+3.9% year on year, +1.0% quarter on quarter), helped by average health plan ticket at R$ 305.9 per month (+5.7% YoY). Adjusted EBITDA fell to R$ 504.4 million (6.3% margin, −5.5 percentage points YoY), and adjusted net income to R$ 12.5 million (0.2% margin). The quarter is a useful read on managed-care economics: top-line growth can persist through repricing even when membership shrinks, but cash medical loss ratio (MLR), seasonality, and litigation-related medical spend can overwhelm the profit line in a single quarter — especially while management runs an operational restructuring focused on contract profitability, cash, and deleveraging.
Hapvida’s release emphasizes cash MLR and cash administrative expenses as operating lenses. The earnings presentation also notes that its monitoring view follows IFRS 4 (insurance contracts under the prior standard), which differs from IFRS 17 figures in statutory CVM filings. When reconciling to filed statements, treat the release as the management narrative and the ITR as the regulatory anchor.
Consolidated snapshot
Figures below follow Hapvida’s 2Q26 results report (13 August 2026), using the company’s cash MLR and adjusted EBITDA / adjusted net income definitions unless noted:
| Metric (2Q26) | Result | vs 2Q25 | vs 1Q26 |
|---|---|---|---|
| Net revenue | R$ 7,974 m | +3.9% | +1.0% |
| Health beneficiaries (EoP) | 8.67 m | −188k | −16k |
| Dental beneficiaries (EoP) | 7.29 m | +261k | +103k |
| Avg monthly health ticket | R$ 305.9 | +5.7% | +0.3% |
| Cash MLR | 75.2% | +1.3 pp | +3.0 pp |
| Cash medical claims | R$ 5,997 m | +5.7% | +5.3% |
| Cash admin + sales | R$ 1,350 m (16.9% ROL) | +3.9 pp | +1.0 pp |
| Adjusted EBITDA | R$ 504 m | −44.3% | −37.2% |
| EBITDA margin | 6.3% | −5.5 pp | −3.9 pp |
| Adjusted net income | R$ 12.5 m | −95.8% | −94.9% |
| Net debt | R$ 5,401 m | +34.4% | +4.6% |
| Net debt / LTM EBITDA (covenant) | 1.61x | +0.66x | +0.22x |
| Capex | R$ 173 m | −12.6% | −9.5% |
In 1H26, net revenue totaled R$ 15.87 billion (+4.6%), cash MLR averaged 73.7% (+0.8 pp vs 1H25), adjusted EBITDA R$ 1.31 billion (−31.5% vs 1H25), and adjusted net income R$ 257 million (−64.2%).
Revenue: repricing vs mix and membership
Health plan net revenue was R$ 7.79 billion in 2Q26 (+3.6% YoY, flat sequentially). Dental revenue reached R$ 226.3 million (−1.6% YoY, +1.9% vs 1Q26), with management citing cross-selling to health members. Hospital and medical services revenue rose 12.7% sequentially to R$ 242.5 million, tied to higher-complexity volume and table repricing in selected regions.
| Revenue line (2Q26) | Amount | YoY |
|---|---|---|
| Health plans | R$ 7,792 m | +3.6% |
| Dental plans | R$ 226 m | −1.6% |
| Medical-hospital services | R$ 243 m | +11.7% |
| Net revenue | R$ 7,974 m | +3.9% |
Ticket growth reflects contract repricing for economic balance, partly offset by mix across regions, products, and channels and by regulated adjustments on individual plans. Management on the call highlighted roughly +6% YoY in average health ticket while membership declined — a pattern consistent with margin-over-volume repositioning.
Membership, contract review, and dental growth
Health beneficiaries ended 2Q26 at 8.67 million, down 16,000 net in the quarter (an improvement versus recent quarters, per the release). Roughly 9,000 of the reduction related to revalued contracts under the new commercial strategy.
| Membership (EoP) | 2Q26 | Change vs 2Q25 |
|---|---|---|
| Health | 8,668k | −188k |
| Dental | 7,293k | +261k |
At end-June 2026, about 947,000 lives (~11% of the base) met stricter profitability and delinquency criteria from the contract review that started late in the quarter. Management stated those lives carry roughly half the consolidated health ticket. Over coming renewal cycles, some may be repriced or discontinued — management expects either outcome to help margin and cash, but the timing is uncertain.
Dental added 103,000 beneficiaries in the quarter, with the release describing the line as mature, high-margin, and supportive of health–dental bundling.
Cash MLR, seasonality, and judicial claims
Cash MLR rose to 75.2% in 2Q26 from 72.2% in 1Q26 and 73.9% in 2Q25. Hapvida attributed much of the sequential move to unfavorable seasonality in line with history, plus a backlog of medical bills following higher utilization into March 2026 (already flagged in 1Q26).
| Cash assistential cost (2Q26) | Amount | Note |
|---|---|---|
| Cash medical claims | (R$ 5,997 m) | +5.7% YoY |
| PEONA | (R$ 14 m) | Lower vs 1Q26 |
| SUS reimbursement provision | (R$ 108 m) | |
| D&A (assistential) | (R$ 163 m) | |
| Total assistential cash costs | (R$ 6,283 m) | MLR 75.2% |
Within contingencies, judicial medical claims (“sinistro judicial”) reached R$ 135.4 million in 2Q26, up R$ 37.4 million versus 1Q26 — a discrete headwind on top of seasonality. Civil litigation expenses in admin also rose (R$ 324.0 million in the quarter, +R$ 72.6 million vs 1Q26), including a R$ 14 million one-off labor item.
Management reiterated structural initiatives on owned and credentialed networks aimed at efficiency and MLR over the next year, without sacrificing care quality.
Admin, sales, and EBITDA bridge
Cash administrative and sales expenses totaled R$ 1.35 billion (16.9% of net revenue), up 3.9 pp YoY and 1.0 pp sequentially.
| Expense bucket (2Q26) | Amount | % ROL |
|---|---|---|
| Cash administrative | (R$ 674 m) | 8.4% |
| Sales | (R$ 677 m) | 8.5% |
| Combined | (R$ 1,350 m) | 16.9% |
Major sequential pressures included contingencies and taxes (+R$ 52.3 million, mostly civil contingencies) and sales commissions (+R$ 36.2 million). Partial offsets: lower ANS fines (−R$ 18.7 million) and net favorable other lines after one-offs tied to retained installments on prior acquisitions.
Adjusted EBITDA at R$ 504 million (6.3% margin) reflects the MLR and cost stack above. Adjusted net income at R$ 12.5 million adds financial and tax effects below EBITDA (the release cites adjusted profit definitions in its reconciliation tables).
Debt, capex, and cash seasonality
Net debt ended 2Q26 at R$ 5.40 billion, up from R$ 5.17 billion in 1Q26 and R$ 4.02 billion in 2Q25. Net debt / LTM EBITDA under the debenture covenant reached 1.61x versus 1.38x in 1Q26 and 0.95x in 2Q25.
Management noted that 2Q cash flow is not fully representative of the year because 2Q–3Q tend to be weaker on claims seasonality while 3Q–4Q are stronger. Excluding roughly R$ 170 million of M&A-related debt, net debt was described as relatively flat quarter on quarter. Capex was R$ 173 million in 2Q26 (R$ 363 million in 1H26).
Restructuring narrative
The release opens with management’s operational restructuring announced early 2026, expected to feed margin, cash generation, and deleveraging gradually. 2Q26 is early in that cycle: revenue still grows on ticket, but MLR, litigation, and portfolio cleanup dominated earnings. ANS complaint index (IGR) figures in the deck show Hapvida improving versus prior quarters — a quality metric investors often watch alongside MLR.
Where to view in the explorer
Sources
- Hapvida Participações e Investimentos S.A. — Relatório de Resultados 2T26 (reference 30 Jun 2026), disclosed 13 August 2026 (CVM IPE chain)
- Hapvida — 2Q26 earnings presentation and conference call transcript, August 2026
- HAPV3 on the explorer — filings and company page
Disclaimer
This article is for informational and educational purposes only. It is not investment advice. Cash MLR, adjusted EBITDA, and adjusted net income follow Hapvida’s release definitions and may differ from IFRS 17 figures in statutory CVM filings. Refer to those official documents and, if needed, a licensed professional.
Trabaja con filings vía API
¿Necesitas acceso programático a DFP, ITR, FRE y más? Usa la API de apicvm.